Business
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
DALLAS, May 05, 2025--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that it has received clearance of its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial for LP-184 in Triple Negative Breast Cancer. This achievement builds on the previous regulatory momentum including Orphan Drug Desi
About this update from Lantern Pharma Inc.
[{"type":"image","alt":"Figure 1: Preclinical PDX Tumor Models & LP-184 Tumor Volume Change. Figure 2: LP-184 Synergy with Olaparib in Treatment Resistant TNBC PDX Models.","displaySize":"","headline":null,"caption":"Figure 1: Preclinical PDX Tumor Models & LP-184 Tumor Volume Change. Figure 2: LP-184 Synergy with Olaparib in Treatment Resistant TNBC PDX Models.","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":266,"url":"https://media.zenfs.com/en/business-wire.com/c65ec4455d362cbc9508b92fd2ec4173"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jz1T88TibeEEiirX7sEeaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c65ec4455d362cbc9508b92fd2ec4173","width":480,"height":266}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/2d4c77a716e1c698066eadba3bedc03a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RlxbBWytsJWQfbnHjq4q4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2d4c77a716e1c698066eadba3bedc03a","width":480,"height":480}}},{"type":"list","items":[{"val":[{"type":"text","content":"The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern’s AI platform, RADR®","length":208,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The phase 1b/2 clinical trial plans to evaluate LP-184 in recurrent TNBC patients as both monotherapy and in combination with olaparib.","length":135,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"This achievement follows the FDA’s Orphan Drug Designation for LP-184 in TNBC in 2023 and FDA Fast Track Designation for LP-184 in TNBC in 2024.","length":144,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The average survival for newly diagnosed, metastatic TNBC is estimated at 18 months and presents an annual market opportunity in excess of $4 billion USD.","length":154,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":641,"olType":false},{"type":"text","content":"DALLAS, May 05, 2025--(BUSI...